Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
:MDWD
MDWD Stock Chart & Stats
$17.71
-$0.64(-3.70%)
At close: 4:00 PM EST
$17.71
-$0.64(-3.70%)
Day’s Range― - ―
52-Week Range$14.14 - $22.51
Previous CloseN/A
Volume29.05K
Average Volume (3M)60.04K
Market Cap
$222.45M
Enterprise Value$148.86M
Total Cash (Recent Filing)$59.09M
Total Debt (Recent Filing)$9.33M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Mar 12, 2026EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding12,821,433
10 Day Avg. Volume101,296
30 Day Avg. Volume60,037
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)5.69
Price to Sales (P/S)8.77
P/FCF Ratio-8.91
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue7.11
Enterprise Value/Gross Profit38.38
Enterprise Value/Ebitda-13.62
Forecast
1Y Price Target
$30.00Price Target Upside69.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.22
Revenue Forecast (FY)$23.14M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe 12-month price target is raised to $36 per diluted share from $31, driven by manufacturing expansion and the expectation of a permanent CPT code.
Manufacturing ExpansionMediWound announced the commissioning of its expanded manufacturing GMP facility for NexoBrid, increasing production capacity sixfold to support growing global demand.
Market Growth OpportunitiesNexoBrid has achieved penetration into over 60 US burn centers, and a permanent US CPT code along with increased drug supply could result in further growth.
Bears Say
Operating LossThe Q3 operating loss was $6.5M, and the net loss was $2.7M.
Revenue Recognition RiskThere is risk of some revenue being recognized in 2026 due to timing of government payments, which may have been delayed by the government shutdown.
Mediwound News
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $14.14 and its highest was $22.50 in the past 12 months.
What is Mediwound’s market cap?
Mediwound’s market cap is $222.45M.
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is Mar 12, 2026 which is in 97 days.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on Nov 20, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.812 by $0.572.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -0.57.
How many shares outstanding does Mediwound have?
Mediwound has 12,821,433 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.812. Following the earnings report the stock price went down -5.599%.
Which hedge fund is a major shareholder of Mediwound?
Currently, no hedge funds are holding shares in MDWD
Mediwound Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (69.40% Upside)
$30.00 (69.40% Upside)
Blogger Sentiment
Bullish
MDWD Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 2.2K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.85%
12-Months-Change
Fundamentals
Return on Equity
-48.83%
Trailing 12-Months
Asset Growth
26.35%
Trailing 12-Months
Company Description
Mediwound
Mediwound Ltd. is a biopharmaceutical company focused on developing and commercializing innovative therapies for wound management and tissue regeneration. The company specializes in advanced therapeutic solutions, particularly its flagship product, NexoBrid, an enzymatic debridement agent for the treatment of severe burn wounds. Mediwound operates primarily in the healthcare sector, targeting hospitals and healthcare providers to improve patient outcomes in wound care.
MDWD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in clinical trials and manufacturing capabilities, as well as strong revenue growth. However, these were offset by increased operating losses and uncertainties related to government contracts and clinical trial timelines.View all MDWD earnings summariesMDWD Stock 12 Month Forecast
Average Price Target
$30.00
▲(69.40% Upside)
Technical Analysis
Lineage Therap
―
Eledon Pharmaceuticals
―
Design Therapeutics
―
Ventyx Biosciences
―
Tevogen Bio Holdings
―
Ownership Overview
―
Insiders
1.72% Mutual Funds
28.35% Other Institutional Investors
66.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---